Table 3: Likelihood that clinicians reported ordering or recommending specific cancer genomic test in the past 12 months, by provider group.

Total
clinicians
PCPsb  
n (column %)c  
adjusted ORd
(95%  CI)e
Naturopaths  
n (column %)c  
adjusted ORd  
(95%  CI)e
OB-GYNs  
n (column %)c  
adjusted ORd  
(95%  CI)e
Specialistsf  
n (column %)c  
adjusted ORd  
(95%  CI)e

BRCA for patients without BCg or OCh,i,j176 (62.6%)51 (53.7%)
1.0 (referent)
14 (36.8%)
0.8 (0.3–1.9)
75 (77.3%)  
2.1 (1.1–4.2)
36 (70.6%)
2.1 (1.0–4.7)k

BRCA for patients with BCg or OCh,i,l91 (63.6%)14 (66.7%)
1.0 (referent)
14 (46.7%)
0.5 (0.1–1.7)
11 (64.7%)
0.5 (0.1–2.1)
52 (69.3%)
0.7 (0.2–2.1)

Lynch syndrome testingm for patients without cancern,o68 (49.6%)9 (25.0%)
1.0 (referent)
4 (50.0%)
3.9 (0.8–20.6)
10 (50.0%)
2.6 (0.8–8.8)
45 (61.6%)
2.2 (0.7–7.3)

Lynch syndrome testingm for patients with cancern,p56 (61.5%)5 (45.5%)
1.0 (referent)
NAqNAq50 (65.8%)
1.5 (0.4–5.5)

aBolded estimates indicate significant findings.
bPCPs: primary care providers include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.
cThe column % reflects the percent responding within each practice category.
dOR: odds ratio.
eCI: confidence interval.
fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.
gBC: breast cancer.
hOC: ovarian cancer.
iAdjusted for number of patients seen per week and confidence in breast and ovarian cancer genetics.
jAmong clinicians who recommend breast and ovarian screening.
k .
lAmong clinicians who treat breast and/or ovarian cancer.
mSpecifically testing for mismatch repair (MMR) genes, which may include testing in MCH1, MSH2, MSH6, and PMS2 genes.
nAdjusted for confidence in knowledge of colorectal cancer genetics.
oAmong clinicians who recommend colorectal cancer screening.
pAmong clinicians who treat colorectal cancer.
qUnable to report estimates due to small cell size.